Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 31

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Neoplasm malignant

Recruiting

Study of ipilimumab and nivolumab injected into tumors before surgery in patients with stage III melanoma that can be removed by surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Unicancer

Triple negative breast cancer

Recruiting

Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Unicancer

Chronic lymphocytic leukaemia+1

Recruiting

A Study of Allo-QuadCAR01-T Cell Therapy for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALLO-QUADCAR01-T
  • Sponsor:Avencell Therapeutics Inc.

Penile squamous cell carcinoma

Recruiting

Study of enfortumab vedotin and avelumab for patients with advanced or metastatic penile cancer that has spread or cannot be removed by surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Non-small cell lung cancer stage IV+2

Recruiting

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Central nervous system lymphoma

Recruiting

Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Colorectal adenocarcinoma+2

Recruiting

Study of chemotherapy drug combination with or without heated chemotherapy in the abdomen for patients with advanced colon cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fundacion Para La Investigacion Biomedica De Cordoba

Triple negative breast cancer

Recruiting

A study comparing datopotamab deruxtecan with durvalumab versus datopotamab deruxtecan alone for patients with PDL1-negative metastatic triple-negative breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:Queen Mary University Of London

Prostate cancer

Recruiting

A study testing ASP5541 compared to abiraterone acetate in patients with advanced prostate cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astellas Pharma Global Development Inc.

Non-small cell lung cancer metastatic

Recruiting

Study of Different Dosing Schedules of Osimertinib in Patients with EGFR Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Db-1303
  • Sponsor:BioNTech SE

Malignant mast cell neoplasm

Recruiting

Study of BNT326 alone and with BNT327 in patients with advanced solid tumors: Testing safety and effectiveness of new cancer treatments

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.